Literature DB >> 16108827

Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice.

Md Zahidunnabi Dewan1, Mariko Watanabe, Sunjida Ahmed, Kazuo Terashima, Sankichi Horiuchi, Tetsutaro Sata, Mitsuo Honda, Mamoru Ito, Toshiki Watanabe, Ryouichi Horie, Naoki Yamamoto.   

Abstract

As there are very few reproducible animal models without conditioning available for the study of human B-cell-type Hodgkin's lymphoma (HL), we investigated the ability of HL cells to induce tumors using novel NOD/SCID/gammac(null) (NOG) mice. Four human Epstein-Barr virus-negative cell lines (KM-H2 and L428 originated from B cells, L540 and HDLM2 originated from T cells) were inoculated either subcutaneously in the postauricular region or intravenously in the tail of unmanipulated NOG mice. All cell lines successfully engrafted and produced tumors with infiltration of cells in various organs of all mice. Tumor cells had classical histomorphology as well as expression patterns of the tumor marker CD30, which is a cell surface antigen expressed on HL. Tumor progression in mice inoculated with B-cell-type, but not T-cell-type, HL cells correlated with an elevation in serum human interleukin-6 levels. Tumor cells from the mice also retained strong nuclear factor (NF)-kappaB DNA binding activity, and the induced NF-kappaB components were indistinguishable from those cultured in vitro. The reproducible growth behavior and preservation of characteristic features of both B-cell-type and T-cell-type HL in the mice suggest that this new xenotransplant model can provide a unique opportunity to understand and investigate the mechanism of pathogenesis and malignant cell growth, and to develop novel anticancer therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16108827     DOI: 10.1111/j.1349-7006.2005.00079.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  5 in total

1.  Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma.

Authors:  K Shimada; S Shimada; K Sugimoto; M Nakatochi; M Suguro; A Hirakawa; T D Hocking; I Takeuchi; T Tokunaga; Y Takagi; A Sakamoto; T Aoki; T Naoe; S Nakamura; F Hayakawa; M Seto; A Tomita; H Kiyoi
Journal:  Leukemia       Date:  2016-03-22       Impact factor: 11.528

2.  T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

Authors:  Antonio Di Stasi; Biagio De Angelis; Cliona M Rooney; Lan Zhang; Aruna Mahendravada; Aaron E Foster; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti; Barbara Savoldo
Journal:  Blood       Date:  2009-04-17       Impact factor: 22.113

3.  Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells.

Authors:  Ken-ichi Imadome; Misako Yajima; Ayako Arai; Atsuko Nakazawa; Fuyuko Kawano; Sayumi Ichikawa; Norio Shimizu; Naoki Yamamoto; Tomohiro Morio; Shouichi Ohga; Hiroyuki Nakamura; Mamoru Ito; Osamu Miura; Jun Komano; Shigeyoshi Fujiwara
Journal:  PLoS Pathog       Date:  2011-10-20       Impact factor: 6.823

4.  Downregulation of AKT/mTOR signaling pathway for Salmonella-mediated autophagy in human anaplastic thyroid cancer.

Authors:  Li-Hsien Wu; Christian R Pangilinan; Che-Hsin Lee
Journal:  J Cancer       Date:  2022-09-06       Impact factor: 4.478

5.  Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies.

Authors:  Radhia M'kacher; Monika Frenzel; Mustafa Al Jawhari; Steffen Junker; Corina Cuceu; Luc Morat; Anne-Laure Bauchet; Lev Stimmer; Aude Lenain; Nathalie Dechamps; William M Hempel; Geraldine Pottier; Leonhard Heidingsfelder; Eric Laplagne; Claire Borie; Noufissa Oudrhiri; Dima Jouni; Annelise Bennaceur-Griscelli; Bruno Colicchio; Alain Dieterlen; Theodore Girinsky; Raphael Boisgard; Jean Bourhis; Jacques Bosq; Thomas Mehrling; Eric Jeandidier; Patrice Carde
Journal:  Cancers (Basel)       Date:  2018-10-31       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.